Vector BioMed Selected as Top Lentiviral Vector Design and Manufacturing Company
Life Sciences Review recognizes the pure-play lentiviral vector company’s work to help Asia-Pacific healthcare providers manufacture CAR-T therapies closer to patients.
GAITHERSBURG, Md., Nov. 9, 2026 — Vector BioMed, a leading lentiviral vector supplier and contract vector development and manufacturing organization (CVDMO), today announced that it has been named Lentiviral Vector Design and Manufacturing Company of the Year in Asia 2026 by Life Sciences Review. The recognition highlights the company’s specialized lentiviral vector expertise and its work helping healthcare providers around the world develop and deliver advanced cell and gene therapies closer to where patients live. [Read more…]
16 CAR-T Therapies and Counting:
How the CAR-T Market Is Evolving and The Companies Leading the Charge
Since 2017, an incredible 16 CAR-T cell therapies have reached commercialization, with several more nearing the finish line. Seven therapies have been approved by the U.S. FDA, after which approvals for them were issued in other major markets as well. These include:
- Kymriah (tisagenlecleucel)
- Yescarta (axicabtagene ciloleucel)
- Tecartus (brexucabtagene autoleucel)
- Breyanzi (lisocabtagene maraleucel)
- Abecma (idecabtagene vicleucel)
- Carvykti (ciltacabtagene autoleucel)
- Aucatzyl (obecabtagene autoleucel)
Beyond the U.S., six CAR-T therapies (Carteyva, Yikaida, Yorwida, Zevor-cel, Fucaso, and Satri-cel) have been approved by China’s National Medical Products Administration (NMPA), including Satri-cel, which made history this year as the world’s first CAR-T cell therapy approved for a solid tumor. [Read more…]
Celaid Therapeutics Raises JPY 400 million in Series B Financing to Advance Ex Vivo Hematopoietic Stem Cell (HSC) Expansion
For decades, hematopoietic stem cell transplantation (HSCT) has been one of the most successful cell therapies in medicine, with more than 40,000 transplants performed worldwide each year. Yet the field has a stubborn problem: not every patient who needs a transplant can get one. Ex vivo hematopoietic stem cell (HSC) expansion was designed to solve it, but progress has been slow. Only a handful of companies have pursued the approach, including Gamida Cell in Israel, ExCellThera in Canada, and Plasticell in the United Kingdom. [Read more…]
The Pipeline for iPSC-Derived Cell Therapeutics in 2027
Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
- 1
- 2
- 3
- …
- 341
- Next Page »